Krishna Institute of Medical Sciences Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 15, 2026
- Posted by: Harsh Piplani
- Category: Results
KIMS share price Rs 766.85 on 15 September 2026, down 0.27%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 37.00 crore. Q2 FY26 base a profit of Rs 72.00 crore.
Quick Answer
The Krishna Institute of Medical Sciences Q2 results date for FY27 is not confirmed, and Krishna Institute of Medical Sciences Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 961.00 crore in revenue and a profit of Rs 72.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Krishna Institute of Medical Sciences Q2 results FY27 announcement is the next scheduled earnings event for Krishna Institute of Medical Sciences Ltd., operates a multi-specialty hospital chain across South India offering tertiary and quaternary care services. The stock traded at Rs 766.85 on the NSE on 15 September 2026, down 0.27% from the previous close of Rs 768.95, about 10.6% below its 52-week high of Rs 858.00 and 33.2% above its 52-week low of Rs 575.80.
What makes the Krishna Institute of Medical Sciences Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 961.00 crore of revenue and a profit of Rs 72.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 1,180.00 crore and a profit of Rs 37.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Krishna Institute of Medical Sciences Q2 Results FY27 Date?
The Krishna Institute of Medical Sciences Q2 results date for FY27 is not confirmed. As of 15 September 2026, Krishna Institute of Medical Sciences Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Krishna Institute of Medical Sciences Q2 results date becomes public through that filing rather than through any advance announcement.
The Krishna Institute of Medical Sciences Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Krishna Institute of Medical Sciences.
Krishna Institute of Medical Sciences Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Krishna Institute of Medical Sciences Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Krishna Institute of Medical Sciences. The Krishna Institute of Medical Sciences Q2 results watchlist below is built from what the company has actually reported and disclosed.
Anyone following Krishna Institute of Medical Sciences Q2 results for the September 2026 quarter will notice a clear divergence in the underlying trend: revenue has grown steadily from Rs 872 crore in Jun25 to Rs 1,180 crore in Jun26, a rise of roughly 35% over five quarters, reflecting continued expansion of the hospital network. Operating profit margin has, however, mildly compressed over the same period, moving from 22% down to 19%, while net profit has fallen much more sharply, from Rs 85 crore in Jun25 to just Rs 33-37 crore in the Mar26 and Jun26 quarters. This gap between rising revenue and shrinking net profit is the single most important trend to watch heading into the September 2026 quarter.
The scale of the net profit decline is larger than the OPM compression alone would suggest, which points to costs below the operating-profit line, such as depreciation and interest, rising as the company continues its expansion capital expenditure. What investors will be watching for in Q2 FY27 is whether net profit stabilizes around the Rs 33-37 crore level seen in the last two quarters or continues to slide even as revenue keeps growing. A repeat of the pattern seen through FY26, where each successive quarter’s net profit came in lower than the one before despite higher sales, would be a meaningful signal for how the company’s expansion is affecting profitability.
The company currently pays no dividend and trades at a very high valuation multiple, which means the market is pricing in an expectation of stronger future earnings or margin recovery rather than rewarding current profitability. Given this, the trajectory of net profit in the September 2026 quarter matters more for sentiment than it might at a business with a more modest valuation. The data available covers standard consolidated hospital-operator financials rounded to the whole crore by the source, so quarter-to-quarter figures should be treated as approximate rather than exact. The Krishna Institute of Medical Sciences Q2 results will therefore carry outsized weight for sentiment relative to the actual profit figure. Investors watching the Krishna Institute of Medical Sciences Q2 results should treat the rounded crore-level figures as approximate. The upcoming Krishna Institute of Medical Sciences Q2 results filing remains the definitive source for exact numbers.
Check Krishna Institute of Medical Sciences Ltd. Live Fundamentals on the Univest Screener
Krishna Institute of Medical Sciences Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Krishna Institute of Medical Sciences Ltd. reported revenue of Rs 1,180.00 crore in Q1 FY27, up 35.32% from Rs 872.00 crore in Q1 FY26, and a profit of Rs 37.00 crore at the net level, down 56.47% from Rs 85.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was up 9.77% over the March 2026 quarter figure of Rs 1,075.00 crore, and net profit was up 12.12% from Rs 33.00 crore in Q4 FY26. Operating margin stood at 22.0% in Q1 FY27 against 21.0% in the September 2025 quarter, which is the comparison the Krishna Institute of Medical Sciences Q2 results print will be read against.
Q2 FY26 Base: The Comparison Krishna Institute of Medical Sciences Q2 Results FY27 Must Beat
Krishna Institute of Medical Sciences Ltd. reported revenue of Rs 961.00 crore and a profit of Rs 72.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Krishna Institute of Medical Sciences Q2 results preview.
Net profit in that base quarter was above the Rs 37.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a demanding level. Revenue of Rs 961.00 crore sits below the Rs 1,180.00 crore of the June 2026 quarter, which frames how much sequential movement the Krishna Institute of Medical Sciences Q2 results print needs to show growth.
Krishna Institute of Medical Sciences Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 961.00 | 72.00 |
| Q3 FY26 (Dec 2025) | 998.00 | 52.00 |
| Q4 FY26 (Mar 2026) | 1,075.00 | 33.00 |
| Q1 FY27 (Jun 2026) | 1,180.00 | 37.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Krishna Institute of Medical Sciences Q2 results preview uses.
Revenue across those four quarters ranged from Rs 961.00 crore to Rs 1,180.00 crore, and net profit from Rs 33.00 crore to Rs 72.00 crore. That spread is the honest context for the Krishna Institute of Medical Sciences Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Krishna Institute of Medical Sciences Q2 Results FY27
The Krishna Institute of Medical Sciences Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Krishna Institute of Medical Sciences has already reported.
Valuation stretched relative to earnings trend
KIMS trades at a price-to-earnings ratio of about 154.57 times based on the market data provided, alongside a price-to-book ratio of roughly 13.65 times against a book value of Rs 56.2 per share. Return on equity is 11.3%, a level that looks modest set against such a high earnings multiple. With net profit having declined over recent quarters even as revenue has grown, this valuation implies the market expects a reversal of the recent profit trend rather than reflecting current earnings power.
Price and technical context
The stock has traded between Rs 575.8 and Rs 858 over the past 52 weeks, with the current price of Rs 766.85 sitting below its 50-day moving average of Rs 790.1 but above its 200-day moving average of Rs 714.6. The relative strength index reads 47.04, roughly in the middle of the typical range, which as a purely technical observation does not point to an overbought or oversold condition either way.
Balance sheet and dividend
The debt-to-equity ratio stands at 1.89, a comparatively higher level of borrowing that is consistent with a hospital operator funding capacity expansion, and ties into the rising depreciation and interest costs flagged as a factor behind the net profit decline. The company pays no dividend at present, so shareholder return depends entirely on the share price and the trajectory of future earnings.
Krishna Institute of Medical Sciences Q2 Results FY27: Share Price and Valuation Going Into the Print
Krishna Institute of Medical Sciences share price today is Rs 766.85 on the NSE, down Rs 2.10 or 0.27% from the previous close of Rs 768.95 on 15 September 2026, ahead of the Krishna Institute of Medical Sciences Q2 results announcement.
| Metric | Value (15 September 2026) |
|---|---|
| NSE Symbol | KIMS |
| Current Market Price | Rs 766.85 |
| 52-Week High | Rs 858.00 |
| 52-Week Low | Rs 575.80 |
| Market Capitalisation | Rs 32206 crore |
| PE Ratio | 154.57 |
| PB Ratio | 13.65 |
| EPS (TTM) | Rs 4.96 |
| Book Value per Share | Rs 56.20 |
| Debt to Equity | 1.89 |
| Return on Equity | 11.3% |
| 50-Day Moving Average | Rs 790.10 |
| 200-Day Moving Average | Rs 714.60 |
| RSI (14) | 47.04 |
The stock trades below its 50-day average of Rs 790.10 but above its 200-day average of Rs 714.60, with a 14-day RSI of 47.04. None of this is a view on where the shares go once the Krishna Institute of Medical Sciences Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Krishna Institute of Medical Sciences Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Krishna Institute of Medical Sciences Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Krishna Institute of Medical Sciences Q2 results print in proportion.
- Revenue against the Rs 961.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 72.00 crore in that same quarter
- Operating margin against 22.0% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Krishna Institute of Medical Sciences Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Krishna Institute of Medical Sciences Q2 Results FY27
The Krishna Institute of Medical Sciences Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Krishna Institute of Medical Sciences Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Krishna Institute of Medical Sciences Q2 results FY27 print faces a base of Rs 961.00 crore in revenue and a profit of Rs 72.00 crore, with the most recent quarter having delivered Rs 1,180.00 crore and a profit of Rs 37.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Krishna Institute of Medical Sciences, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Krishna Institute of Medical Sciences Q2 Results FY27
What is the Krishna Institute of Medical Sciences Q2 results date for FY27?
Ans. The Krishna Institute of Medical Sciences Q2 results date for FY27 is not confirmed. Krishna Institute of Medical Sciences Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Krishna Institute of Medical Sciences Q2 results 2026 cover?
Ans. The Krishna Institute of Medical Sciences Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Krishna Institute of Medical Sciences Ltd. reports revenue, operating profit and net profit for that period, and the Krishna Institute of Medical Sciences Q2 results filing also carries the notes to the accounts.
What were the Krishna Institute of Medical Sciences Q1 FY27 results?
Ans. Krishna Institute of Medical Sciences Ltd. reported revenue of Rs 1,180.00 crore in Q1 FY27 and a profit of Rs 37.00 crore at the net level. Revenue was up 35.32% versus Q1 FY26 and net profit was down 56.47% from Rs 85.00 crore in Q1 FY26.
What were Krishna Institute of Medical Sciences Q2 FY26 results in the September 2025 quarter?
Ans. Krishna Institute of Medical Sciences Ltd. reported revenue of Rs 961.00 crore and a profit of Rs 72.00 crore in Q2 FY26. Operating margin was 21.0%. Those figures form the base for the Krishna Institute of Medical Sciences Q2 results FY27 comparison.
What are the main Krishna Institute of Medical Sciences Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Krishna Institute of Medical Sciences Q2 results expectations centre on revenue against the Rs 961.00 crore base, net profit against a profit of Rs 72.00 crore, operating margin against 22.0% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Krishna Institute of Medical Sciences share price today ahead of the Q2 earnings?
Ans. Krishna Institute of Medical Sciences share price is Rs 766.85 on the NSE as of 15 September 2026, down 0.27% from Rs 768.95. The stock is about 10.6% below its 52-week high of Rs 858.00 and 33.2% above its 52-week low of Rs 575.80, at a market capitalisation of Rs 32206 crore.
Is Krishna Institute of Medical Sciences a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Krishna Institute of Medical Sciences Ltd. The stock trades at a price-to-book ratio of 13.65 with a return on equity of 11.3%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
